On Thursday, Exelixis hit a noteworthy performance benchmark, with its Relative Strength (RS) Rating rising into the 90-plus percentile with an improvement to 93, up from 87 the day before.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
History reveals that the market's biggest winners typically have an 80 or better RS Rating in the early stages of their moves.
How To Use Stock Charts To Stay Profitable And Protected
Exelixis is now considered extended and out of buy range after clearing a 27.53 buy point in a first-stage flat base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Earnings growth picked up last quarter from 171% to 370%. But sales fell from 36% to 14%.
The company holds the No. 2 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics is the top-ranked stock within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
